TAIPEI MEDICAL UNIVERSITY

Despite declining trends, 1 in 6 US adults with asthma still don't adhere to treatment due to costs, per a study in Thorax. Cost-related non-adherence (CRN) was linked to higher risks of asthma attacks and ER visits. Factors like age, gender, and ethnicity influenced CRN prevalence.

The Fourth Asia-Pacific Forum on Precision Cancer Treatment highlighted advancements in breast and lung cancer care, focusing on liquid biopsy, personalized therapies, and in-depth genetic profiling. Experts discussed how these innovations enhance early detection, monitor tumor heterogeneity, and tailor treatments to improve outcomes. The forum emphasized the importance of a complete ecosystem in precision medicine, spanning detection to treatment, and the role of international collaboration in advancing cancer care.

1 in 6 U.S. adults with asthma can't afford medications, risking asthma attacks and ER visits. Cost-related medication non-adherence has declined from 23% in 2011 to 13% in 2022, possibly due to the Affordable Care Act and Medicaid expansion. The Biden Administration's Inflation Reduction Act could further reduce costs if asthma medications are included in future negotiations.

Ainos partners with Taiwan Tanabe Seiyaku to advance low-dose interferon alpha for Sjögren’s disease in Taiwan, aiming to accelerate global market entry. Ainos plans a new clinical trial in Taiwan to evaluate Veldona’s efficacy in primary Sjögren’s, with trial completion expected by end of 2026.

Ainos received IRB approval from Shuang Ho Hospital for a clinical trial of VELDONA in treating Sjogren’s syndrome, aiming to improve salivary gland function and alleviate dryness symptoms. The trial, managed by ComboTrial Consultancy Ltd., will recruit 24 patients for a 24- to 48-week treatment period, with primary and secondary endpoints focused on efficacy and symptom improvements. Ainos plans to submit to Taiwan’s FDA by end-2024, anticipating all approvals by Q1 2025, with the study completion by end-2026.

Ainos, Inc. received IRB approval from Shuang Ho Hospital for a clinical trial of VELDONA® in treating Sjögren's syndrome, with a planned site initiation visit in April 2025. The study aims to assess VELDONA®'s potential in improving salivary gland function and alleviating dryness symptoms.

Ainos receives IRB approval for VELDONA® clinical trial treating Sjögren's syndrome at Shuang Ho Hospital; plans site initiation visit in April 2025, pending regulatory approvals. The study will recruit 24 patients for a 24- to 48-week treatment period, with patient recruitment starting in May 2025 and study completion expected by December 2026.

Oneness Biotech and Microbio (Shanghai) announce SNS812, a pan-COVID new drug, achieved statistical significance in Phase 2 trial, demonstrating broad-spectrum efficacy and safety against various virus strains, including JN.1 and high immune-escape variants.